EDEN PRAIRIE, Minn., April 02, 2018 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq:CHFS), today announces that it will present at The MicroCap Conference on April 9, 2018.
The company’s CEO, John Erb, will present at 2:00 PM ET at The Essex House in New York City. The company will also be available for one-on-one investor meetings. Interested investors may request a meeting time by contacting Bret Shapiro, COREIR, either by calling 516-222-2560 or via firstname.lastname@example.org.
About CHF Solutions
CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
JQA Partners, Inc.
Source: CHF Solutions, Inc.